Determinants of the tropism of SARS-CoV-2 and other coronaviruses in 3D models of human lung epithelia

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • start year

    -99
  • Known Financial Commitments (USD)

    $0
  • Funder

    DIM-ELICIT
  • Principal Investigator

    Lisa Chakrabarti, Samy Gobaa
  • Research Location

    France
  • Lead Research Institution

    HIV immune control and Biomaterials & Microfluidity at the Institut Pasteur
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Disease pathogenesis

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The reasons for the severity of infection with SARS-CoV-2, a virus that induces a case fatality rate greater than 1% in symptomatic patients, are not understood. Pathological data indicate that this virus infects the respiratory tract and pulmonary alveoli, which likely contributes to the severe pneumonia characteristic of COVID-19 syndrome. However, the determinants responsible for this tropism and the precise nature of the target cells in the human respiratory tract remain to be explored. For this purpose, we propose to use 3D culture systems that mimic the architecture, cell composition and functions of pulmonary epithelia. We will compare the tropism of SARS-CoV-2 and more benign human coronaviruses for primary epithelia of the upper and lower respiratory tract, to determine whether the tropism is associated with pathogenicity. We will use models based on human airway epithelia reconstructed with fully differentiated hair cells, which can express high levels of coronavirus entry cofactors. We will also take advantage of "lung-on-a-chip" technology that mimics lung alveolar stretching associated with breathing to develop physiologically relevant models of SARS-CoV-2 infection.